

# Accepted Manuscript

An Inter-Company Perspective on Biopharmaceutical Drug Product Robustness Studies

Sorina Morar-Mitrica, Monica L. Adams, George Crotts, Christine Wurth, Peter M. Ihnat, Tanvir Tabish, Valentyn Antochshuk, Willow DiLuzio, Daniel Dix, Jason Fernandez, Kapil Gupta, Michael S. Fleming, Bing He, James K. Kranz, Dingjiang Liu, Chakravarthy Narasimhan, Eric Routhier, Kathy Taylor, Nobel Truong, Elaine Stokes

PII: S0022-3549(17)30715-3

DOI: [10.1016/j.xphs.2017.10.017](https://doi.org/10.1016/j.xphs.2017.10.017)

Reference: XPHS 965

To appear in: *Journal of Pharmaceutical Sciences*

Received Date: 6 April 2017

Revised Date: 5 October 2017

Accepted Date: 6 October 2017

Please cite this article as: Morar-Mitrica S, Adams ML, Crotts G, Wurth C, Ihnat PM, Tabish T, Antochshuk V, DiLuzio W, Dix D, Fernandez J, Gupta K, Fleming MS, He B, Kranz JK, Liu D, Narasimhan C, Routhier E, Taylor K, Truong N, Stokes E, An Inter-Company Perspective on Biopharmaceutical Drug Product Robustness Studies, *Journal of Pharmaceutical Sciences* (2017), doi: 10.1016/j.xphs.2017.10.017.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**An Inter-Company Perspective  
on Biopharmaceutical Drug Product Robustness Studies**

Sorina Morar-Mitrica<sup>1,\*</sup>, Monica L. Adams<sup>2</sup>, George Crotts<sup>1</sup>, Christine Wurth<sup>3</sup>, Peter M. Ihnat<sup>4</sup>,  
Tanvir Tabish<sup>5</sup>, Valentyn Antochshuk<sup>6</sup>, Willow DiLuzio<sup>7</sup>, Daniel Dix<sup>8</sup>, Jason Fernandez<sup>9</sup>, Kapil  
Gupta<sup>9</sup>, Michael S. Fleming<sup>10</sup>, Bing He<sup>11</sup>, James K. Kranz<sup>11</sup>, Dingjiang Liu<sup>8</sup>, Chakravarthy  
Narasimhan<sup>6</sup>, Eric Routhier<sup>12</sup>, Kathy Taylor<sup>11</sup>, Nobel Truong<sup>7</sup>, Elaine Stokes<sup>13</sup>

<sup>1</sup> *Biopharmaceutical Product Sciences, GlaxoSmithKline R&D, 709 Swedeland Road, King of Prussia, PA 19406, USA*

<sup>2</sup> *Drug Product Science and Technology, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, NJ 08903, USA*

<sup>3</sup> *Pharmaceutical Development & Supplies, PTB Biologics Europe, F. Hoffmann-La Roche Ltd., Basel, Switzerland*

<sup>4</sup> *Biologics Preformulation and Drug Product Development, Abbvie Bioresearch Center, Worcester, MA 01605, USA*

<sup>5</sup> *Shire Pharmaceuticals, Industriest. 72, 1221 Vienna, Austria*

<sup>6</sup> *Merck & Co., Inc., Biologics and Vaccines Development, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA*

<sup>7</sup> *Formulation Development, Takeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, MA 02139, USA*

<sup>8</sup> *Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA*

<sup>9</sup> *Biogen, 14 Cambridge Center, Cambridge, MA 02142, USA*

<sup>10</sup> *Analytical & Pharmaceutical Sciences, ImmunoGen, Inc., 830 Winter Street, Waltham, MA 02145, USA*

<sup>11</sup> *Shire, 300 Shire Way, Lexington, MA 02421, USA*

<sup>12</sup> *Pharmaceutical Development, Alexion Pharmaceuticals Inc., 100 College Street, New Haven, CT 06510, USA*

<sup>13</sup> *BioPhorum Operations Group, Sharrow Vale Road, Sheffield, S11 8YZ, United Kingdom*

\* Correspondence to: sorina.2.morar-mitrica@gsk.com

Download English Version:

<https://daneshyari.com/en/article/8513445>

Download Persian Version:

<https://daneshyari.com/article/8513445>

[Daneshyari.com](https://daneshyari.com)